Skip to content

Combined rhEPO and Iron sucorse usage on Cardiac Surgery patients to reduce transfusion

Combined rhEPO and Iron sucorse usage on Cardiac Surgery patients to reduce transfusion - CEICS randomized trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066165
Enrollment
Unknown
Registered
2022-11-25
Start date
2022-11-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease

Interventions

Control group:Iron sucorse
Test group:Iron sucorse + rhEPO

Sponsors

Fuwai hospital, CAMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients schedual to recieve on-pump coronary artery graft surgery for first time with age between 18-80 years old. 2. Pre-surgery blood test shows hemoglobin level64.44umol/L(360ug/dl) or transferrin saturation TS<20%.

Exclusion criteria

Exclusion criteria: 1. Non iron deficiency anemia (such as thalassemia); 2. Baseline hemoglobin level lower than 100g/L; 3. Iron overload (ferritin>300ug/L), or hematocrit>45%; 4. Hypercoagulation, thromboembolic tendency, past history including deep vein thrombosis, within acute stage of myocardial infarction, stroke or pulmonary embolism. Intracardiac thrombosis, shedding and peripheral embolism; 5. Severe coronary artery stenosis with refractory angina under adequate drug treatment; 6. Poorly controlled hypertension or diabetes, in the state of hypertension emergency, subacute or diabetes ketosis; 7. Past history of chronic kidney disease or usage of rhEPO or similar drugs; 8. Reoperation or emergency operation; 9. EF<30% before operation, or in the state of cardiac shock requiring endotracheal intubation or mechanically assisted; 10. Any additional cardiac surgery other than left atrial appendage resection; 11. Malignant tumors or other serious systemic diseases; 12. Subjects with irreversible failure of any important organs; 13. Allergy to rhEPO, iron or any experimental drug; 14. Participated in other clinical trials involving drugs or devices within 30 days.

Design outcomes

Primary

MeasureTime frame
Perioperative period transfusion rate;

Secondary

MeasureTime frame
Perioperative period transfusion volumn;

Countries

China

Contacts

Public ContactWang Xianqiang

Fuwai hospital, CAMS

jinzejian@fuwaihospital.org+86 131 4620 9120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026